<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191826</url>
  </required_header>
  <id_info>
    <org_study_id>SOMCT01-C</org_study_id>
    <secondary_id>2014-001586-27</secondary_id>
    <nct_id>NCT02191826</nct_id>
  </id_info>
  <brief_title>Study of SOM0226 in Familial Amyloid Polyneuropathy</brief_title>
  <official_title>Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOM Biotech SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SOM Biotech SL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label interventional Phase IIa proof of concept clinical trial designed in
      two phases separated by a washout period of 6 weeks (± 2 weeks) , to evaluate the TTR
      stabilization activity of SOM0226 in healthy volunteers (wild type), TTR-FAP patients and
      asymptomatic carriers.

        -  Phase A (24 hours): SOM0226 single dose

        -  Phase B (32 hours): SOM0226 multiple dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTR stabilization</measure>
    <time_frame>24 hours and 32 hours</time_frame>
    <description>TTR stabilization will be measured by determining the concentration of tetrameric TTR after denaturation. The ratio of TTR tetramer after denaturation / TTR tetramer before denaturation of plasma samples from treated subjects will be compared to their baseline ratio. TTR stabilization will be determined as percentage of the baseline ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics assessment</measure>
    <time_frame>24 hours and 32 hours</time_frame>
    <description>Determine the minimal molar ratio SOM0226:TTR that must be reached in plasma to confer maximal TTR stabilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 hours</time_frame>
    <description>Drug safety will be assessed by blood biochemistry and hematology analysis, patient exploration and adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Familial Amyloid Polyneuropathy (FAP)</condition>
  <arm_group>
    <arm_group_label>SOM0226 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOM0226 multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOM0226</intervention_name>
    <description>Oral</description>
    <arm_group_label>SOM0226 single dose</arm_group_label>
    <arm_group_label>SOM0226 multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study

          -  Male or Female, aged 18 years or above at the time of consent

          -  Two cohorts defined by TTR variant (wild type: healthy volunteers; TTR mutant:
             asymptomatic carriers with documented mutation in TTR or diagnosed TTR-FAP patients
             (stage 1 or 2) not undergoing pharmacological treatment with Vyndaqel

          -  Body Mass Index (BMI) &gt; 17.5 kg/m2

          -  Female participants of child bearing potential and male participants whose partner is
             of child bearing potential must be willing to ensure that they or their partner use
             effective contraception during the study and for 2 month thereafter

          -  Able (in the Investigators opinion) and willing to comply with all study requirements

        Exclusion Criteria:

          -  Female participant who is pregnant, lactating or planning pregnancy during the course
             of the study

          -  Evidence of history of clinically significant hepatic disease

          -  An ALT or AST measurement &gt; 2 times the ULN (Upper Limit of Normal)

          -  Scheduled elective surgery or other procedures requiring general anaesthesia during
             the study

          -  Donation of blood during the study or within the past 4 weeks

          -  Treatment (during the study or within the past 4 weeks) with a prescription or
             investigational drug for the treatment of TTR amyloidosis

          -  Treatment with NSAIDs (nonsteroidal antiinflammatory drug) during the study or within
             the past 4 weeks. The following NSAID are allowed: acetylsalicylic acid, etodolac,
             ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam and
             sulindac
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Gámez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.sombiotech.com</url>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transthyretin</keyword>
  <keyword>TTR</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>SOM0226</keyword>
  <keyword>Familiar Amyloid Polyneuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

